Dianthus Therapeutics stock soars 25% on positive trial data

LootboxPhobia · 2026-03-09T21:25:16+00:00

Dianthus Therapeutics Inc. announced a fourth-quarter loss of -$1.43 per share, revenue of $280,000, with the stock price up 25.05% in pre-market trading. The company announced that the claseprubart trial has reached the GO decision ahead of schedule, with further data expected by the end of 2026. The net loss for 2025 is $162.3 million, with R&D expenses significantly increasing, and cash reserves supporting operations until 2028.

LootboxPhobia

2026-03-09 21:25:16

Abstract generation in progress

New York - Monday, Dianthus Therapeutics Inc. (NASDAQ:DNTH) announced a fourth-quarter loss of $1.43 per share, with quarterly revenue of $280,000 as of December 31, 2025.

The biotech company’s stock surged 25.05% in pre-market trading.

The company announced an early go decision for its Phase 3 CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP), reaching the target of 20 confirmed responders with fewer than 40 planned participants completing the open-label Part A.

This early go decision was made ahead of the Q2 2026 guidance, based on a response rate of 50% or higher meeting the go criteria. Dianthus expects to provide topline data for Part B of CAPTIVATE by the end of 2026.

Dianthus Therapeutics CEO Marino Garcia said, “It’s exciting to be part of a company developing potentially best-in-class therapies for patients with severe autoimmune diseases.”

For the full year 2025, the company reported a net loss of $162.3 million, or $4.20 per share, compared to a net loss of $85 million, or $2.55 per share, in 2024.

R&D expenses increased year-over-year from $83.1 million to $145.6 million, mainly due to higher clinical costs and milestone payments for DNTH212.

As of December 31, 2025, the company’s cash, cash equivalents, and investments totaled $514.4 million, expected to support operations through 2028.

Dianthus plans to initiate a Phase 3 registration trial of claseprubart for systemic myasthenia gravis in mid-2026, with topline results expected in the second half of 2028.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes